SGA 9178
In CommitteeSenate
PATRICK GALLAHER
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill formally appoints Patrick Gallagher as a member of the Pharmacy Quality Assurance Commission, filling a vacancy. His term will last nearly four years, ending in January 2028.
- Appoints Patrick Gallagher to the Pharmacy Quality Assurance Commission
- Sets his term to expire on January 19, 2028
- Appointment is effective November 4, 2024
Who is affected
- Pharmacy professionals and pharmacies in Washington — Patrick Gallagher will serve as a voting member of the Pharmacy Quality Assurance Commission, helping oversee pharmacy licensing, discipline, and quality standards.
Who Is Most Affected
As the appointee, Gallagher gains a formal leadership role with authority over pharmacy regulation, licensing, and enforcement — but this is a standard gubernatorial appointment with no special privileges beyond the term itself.
The Pharmacy Quality Assurance Commission (PQAC) regulates pharmacists, pharmacies, and drug dispensing practices; Gallagher’s appointment may influence regulatory priorities, but no change in statutory authority or composition rules is specified.
As a routine gubernatorial appointment to fill a vacancy, this bill has no fiscal impact and does not alter funding, taxes, or spending — state and local governments experience no budgetary effect.
Patients and consumers rely on PQAC for oversight of pharmacy safety and licensing; however, this appointment alone does not signal any change in policy direction, enforcement priorities, or consumer protections.
This bill does not create new regulatory burdens, exemptions, or licensing changes — it only fills an existing seat, so pharmaceutical manufacturers and distributors face no new compliance requirements or market impacts.